(NASDAQ: FENC) Fennec Pharmaceuticals's forecast annual revenue growth rate of 32.49% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.9%.
Fennec Pharmaceuticals's revenue in 2026 is $59,221,000.On average, 8 Wall Street analysts forecast FENC's revenue for 2026 to be $2,582,801,462, with the lowest FENC revenue forecast at $2,434,081,641, and the highest FENC revenue forecast at $2,724,718,254. On average, 8 Wall Street analysts forecast FENC's revenue for 2027 to be $3,688,013,112, with the lowest FENC revenue forecast at $3,116,979,495, and the highest FENC revenue forecast at $3,995,201,425.
In 2028, FENC is forecast to generate $4,839,618,614 in revenue, with the lowest revenue forecast at $3,800,929,364 and the highest revenue forecast at $5,726,467,065.